Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics

Aurinia Pharmaceuticals Inc (AUPH)

Today's Latest Price: $14.95 USD

0.01 (-0.07%)

Updated Sep 17 6:55pm

Add AUPH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 232 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AUPH Stock Summary

  • AUPH's price/sales ratio is 5,255.93; that's higher than the P/S ratio of 99.77% of US stocks.
  • With a year-over-year growth in debt of 1,405.34%, Aurinia Pharmaceuticals Inc's debt growth rate surpasses 98.51% of about US stocks.
  • As for revenue growth, note that AUPH's revenue has grown -31.32% over the past 12 months; that beats the revenue growth of only 7.81% of US companies in our set.
  • Stocks that are quantitatively similar to AUPH, based on their financial statements, market capitalization, and price volatility, are RVNC, VTVT, ADVM, AIMT, and VNRX.
  • Visit AUPH's SEC page to see the company's official filings. To visit the company's web site, go to
AUPH Daily Price Range
AUPH 52-Week Price Range

AUPH Stock Price Chart Technical Analysis Charts

AUPH Price/Volume Stats

Current price $14.95 52-week high $21.93
Prev. close $14.96 52-week low $3.52
Day low $14.73 Volume 661,000
Day high $15.04 Avg. volume 1,506,529
50-day MA $14.36 Dividend yield N/A
200-day MA $16.27 Market Cap 1.89B

Aurinia Pharmaceuticals Inc (AUPH) Company Bio

Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.

AUPH Latest News Stream

Event/Time News Detail
Loading, please wait...

AUPH Latest Social Stream

Loading social stream, please wait...

View Full AUPH Social Stream

Latest AUPH News From Around the Web

Below are the latest news stories about Aurinia Pharmaceuticals Inc that investors may wish to consider to help them evaluate AUPH as an investment opportunity.

Hedge Funds Can’t Stop Buying Aurinia Pharmaceuticals Inc (AUPH)

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | September 16, 2020

Aurinia Pharmaceuticals Inc (AUPH) Investor Presentation - Slideshow

The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences:

Yahoo | September 10, 2020

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83 USD, the closing trading price on August 31,

Business Wire | September 4, 2020

Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2020 Results - Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Results Earnings Conference Call August 11, 2020, 04:30 PM ET Company Participants Glenn Schulman - SVP, Corporate Communications and IR Peter Greenleaf - CEO and Director Neil Solomons - Chief Medical Officer Max Colao - Chief Commercial Officer Joe Miller - Chief Financial Officer...

SA Transcripts on Seeking Alpha | August 12, 2020

Read More 'AUPH' Stories Here

AUPH Price Returns

1-mo 3.10%
3-mo -10.59%
6-mo 23.55%
1-year 142.30%
3-year 140.74%
5-year 337.13%
YTD -26.21%
2019 197.07%
2018 50.55%
2017 115.71%
2016 -14.98%
2015 -32.14%

Continue Researching AUPH

Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:

Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8115 seconds.